AR033379A1 - Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR033379A1
AR033379A1 ARP010103052A ARP010103052A AR033379A1 AR 033379 A1 AR033379 A1 AR 033379A1 AR P010103052 A ARP010103052 A AR P010103052A AR P010103052 A ARP010103052 A AR P010103052A AR 033379 A1 AR033379 A1 AR 033379A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
alkyl
ring
attached
Prior art date
Application number
ARP010103052A
Other languages
English (en)
Inventor
Gilbert Lavielle
Olivier Muller
Mark Millan
Anne Dekeyne
Mauricette Brocco
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR033379A1 publication Critical patent/AR033379A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos de difenilurea de formula (1) en la cual R1, R2, R3 y R4 representan independientemente un átomo de hidrogeno, un átomo de halogeno o un grupo alquilo, alcoxi, hidroxi, alquiltio, mercapto, ciano, amino (opcionalmente substituido por uno o dos grupos alquilo), nitro, carboxi, alcoxicarbonilo, aminocarbonilo (opcionalmente substituido por uno o dos grupos alquilo) o carbamoilo, o en pares, forman conjuntamente con los átomos de carbono a los cuales están unidos, un anillo fenilo o un heterociclo aromático que tiene entre 5 y 7 miembros de anillo y que contiene entre 1 y 3 heteroátomos seleccionados entre nitrogeno, oxígeno y azufre, L1 y L2 cada uno representa un átomo de hidrogeno o conjuntamente forman un grupo -CH2-CH2-, X1 adosado en la posicion 2 o 3 del anillo aromático, representa un enlace, y en ese caso X2 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo, alcoxi, hidroxi, nitro o ciano, o un grupo amino (opcionalmente substituido por uno o dos grupos alquilo), o, X1 y X2, conjuntamente con dos átomos de carbono adyacentes a los cuales están unidos en la posicion 2, 3 o 4 del anillo aromático, forman un grupo cicloalquilo (C4-7), en el cual uno o dos grupos -CH2- del anillo cicloalquilo están opcionalmente reemplazados por un átomo de oxígeno o un grupo NH (opcionalmente substituido por un grupo alquilo), y en el cual un átomo de carbono del anillo cicloalquilo está substituido por el grupo G, X3 representa un átomo de hidrogeno, un átomo de halogeno, un grupo alquilo, alcoxi, hidroxi, nitro o ciano, o un grupo amino (opcionalmente substituido por uno o dos grupos alquilo), G representa un grupo seleccionado entre las formulas G1, G2, G3 y G4 en las cuales: las líneas entrecortadas indican la presencia opcional de un enlace doble, Alk representa un grupo alquileno (C1-6) lineal o ramificado en el cual, cuando G1 o G2 contiene un grupo imidazolina, el grupo Alk- está adosado en la posicion 2 del anillo, n es 0 o 1, T3 representa un grupo alquilo, arilo opcionalmente substituido, arilalquilo opcionalmente substituido, heteroarilo opcionalmente substituido o heteroarilalquilo opcionalmente substituido, T4 representa un grupo alquilo, arilo opcionalmente substituido, arilalquilo opcionalmente substituido, heteroarilo opcionalmente substituido o heteroarilalquilo opcionalmente substituido, enantiomeros y diastereoisomeros de los mismos, y también las sales de adicion de los mismos con un ácido o una base farmacéuticamente aceptable. Procedimiento para su preparacion y composiciones farmacéuticas que los contienen. Los compuestos son utiles como ligandos a2/5-HT2c mixtos y en consecuencia, son utiles en el tratamiento de la depresion, ansiedad, esquizofrenia, enfermedad de Parkinson, alteraciones cognitivas, alteraciones de la libido y disfuncion sexual, alteraciones del sueno, abuso de drogas, y alteraciones de comportamiento impulsivo.
ARP010103052A 2000-06-29 2001-06-27 Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen AR033379A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008378A FR2810979B1 (fr) 2000-06-29 2000-06-29 Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR033379A1 true AR033379A1 (es) 2003-12-17

Family

ID=8851854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103052A AR033379A1 (es) 2000-06-29 2001-06-27 Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Country Status (24)

Country Link
US (2) US6784183B2 (es)
EP (1) EP1170288B9 (es)
JP (1) JP3933889B2 (es)
KR (1) KR100485018B1 (es)
CN (1) CN1241916C (es)
AR (1) AR033379A1 (es)
AT (1) ATE273283T1 (es)
AU (1) AU780022B2 (es)
BR (1) BR0102607A (es)
CA (1) CA2352405C (es)
DE (1) DE60104776T2 (es)
DK (1) DK1170288T3 (es)
EA (1) EA005128B1 (es)
ES (1) ES2227088T3 (es)
FR (1) FR2810979B1 (es)
HK (1) HK1042698B (es)
HU (1) HUP0102723A3 (es)
NO (1) NO320310B1 (es)
NZ (1) NZ512658A (es)
PL (1) PL348392A1 (es)
PT (1) PT1170288E (es)
SI (1) SI1170288T1 (es)
TR (1) TR200402069T4 (es)
ZA (1) ZA200105394B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
EP1610753A4 (en) * 2003-02-20 2007-07-04 Encysive Pharmaceuticals Inc UROTENSIN-II RECEPTOR ANTAGONISTS OF PHENYLENEDIAMINE AND ANTAGONISTS OF CCR-9
EP1558582B1 (en) * 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
FR2859723B1 (fr) * 2003-09-16 2005-10-21 Servier Lab Nouveaux derives de benzoindoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE521589T1 (de) 2003-09-25 2011-09-15 Dompe Spa Amidine und derivate davon und pharmazeutische zusammensetzungen, die diese enthalten
ATE548353T1 (de) * 2004-03-23 2012-03-15 Arena Pharm Inc Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2465469T3 (es) 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
US20080200530A1 (en) * 2005-01-19 2008-08-21 Unett David J Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007136689A2 (en) 2006-05-18 2007-11-29 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2018371B1 (en) 2006-05-18 2015-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CN100390150C (zh) * 2006-06-05 2008-05-28 吴汝林 盐酸咪唑苯脲的制备方法
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
MX2009008777A (es) 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
EP2398776A1 (en) 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EA031470B1 (ru) * 2013-03-15 2019-01-31 Бристол-Майерс Сквибб Компани Ингибиторы ido
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000543A1 (en) * 1979-08-23 1981-03-05 Caterpillar Tractor Co Track assembly anti-torsion chains and method
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
WO1995006044A1 (en) * 1993-08-20 1995-03-02 Smithkline Beecham Plc Amide and urea derivatives as 5ht1d receptor antagonists
GB9420999D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
JP2001508767A (ja) * 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
EP0975614A1 (en) * 1997-04-18 2000-02-02 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Also Published As

Publication number Publication date
PL348392A1 (en) 2002-01-02
NO320310B1 (no) 2005-11-21
KR100485018B1 (ko) 2005-04-25
EA200100600A2 (ru) 2002-02-28
DE60104776D1 (de) 2004-09-16
EP1170288B1 (fr) 2004-08-11
PT1170288E (pt) 2004-10-29
HUP0102723A3 (en) 2002-11-28
TR200402069T4 (tr) 2004-09-21
HUP0102723A2 (hu) 2002-03-28
JP2002037778A (ja) 2002-02-06
EA200100600A3 (ru) 2002-04-25
FR2810979A1 (fr) 2002-01-04
US20020025965A1 (en) 2002-02-28
HK1042698B (zh) 2006-08-11
BR0102607A (pt) 2002-05-28
US7026357B2 (en) 2006-04-11
ATE273283T1 (de) 2004-08-15
SI1170288T1 (en) 2004-12-31
NZ512658A (en) 2002-10-25
EA005128B1 (ru) 2004-12-30
JP3933889B2 (ja) 2007-06-20
US20040224993A1 (en) 2004-11-11
KR20020002249A (ko) 2002-01-09
ZA200105394B (en) 2002-01-31
FR2810979B1 (fr) 2002-08-23
AU5414401A (en) 2002-01-03
HU0102723D0 (en) 2001-08-28
CA2352405A1 (fr) 2001-12-29
ES2227088T3 (es) 2005-04-01
EP1170288B9 (fr) 2005-01-26
CN1337395A (zh) 2002-02-27
CA2352405C (fr) 2006-10-03
NO20013254D0 (no) 2001-06-28
EP1170288A3 (fr) 2002-01-16
US6784183B2 (en) 2004-08-31
EP1170288A2 (fr) 2002-01-09
HK1042698A1 (en) 2002-08-23
AU780022B2 (en) 2005-02-24
CN1241916C (zh) 2006-02-15
DK1170288T3 (da) 2004-11-29
NO20013254L (no) 2001-12-31
DE60104776T2 (de) 2005-09-01

Similar Documents

Publication Publication Date Title
AR033379A1 (es) Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE20020566A1 (es) DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA
AR036659A1 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
RS52978B (en) FUSIONED AMINO PIRIDIN AS HSP90 INHIBITORS
AR054799A1 (es) Derivados de oxindol
DK1263730T3 (da) Aminderivater til behandling af apoptose
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR038044A1 (es) Compuesto derivado de pirazina, composicion farmaceutica, su uso en la fabricacion de un medicamento, proceso para su preparacion y compuesto intermediario en dicho proceso.
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR030558A1 (es) COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR054102A1 (es) Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
AR031526A1 (es) Nuevas fenilpiperazinas, composiciones farmaceuticas que las contienen, metodos para preparar los compuestos y las composiciones y uso de los compuestos en la preparacion de un medicamento.
AR054045A1 (es) Compuestos benzoimidazol sustituidos con actividad dual no inhibitoria y mu opioide agonista
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ES2253568T3 (es) Compuestos heterociclicos para el uso en el tratamiento de los trastornos de las vias urinarias.
AR057005A1 (es) Derivados de 4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina, una composicion farmaceutica y uso del compuesto para preparar un medicamento
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR041882A1 (es) Compuestos de imidazopiridina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso

Legal Events

Date Code Title Description
FG Grant, registration